M&A fever

April 2009
Pharmaceutical Representative;Apr2009, Vol. 39 Issue 4, p8
The article reports on the acquisition of Schering-Plough Corp. by Merck & Co. Inc. It mentions that Merck has refused to get consolidated with other pharmaceutical companies for several times and cites its decision to procure Schering worth $41 billion. Furthermore, Merck's deal with Schering will end in 2009.


Related Articles

  • Pharma Mergerpalooza.  // Pharmaceutical Executive;Apr2009, Vol. 29 Issue 4, p11 

    The article reports on the latest merger activities of the pharmaceutical industry in the U.S. Merck & Co. Inc. has entered a reverse merger agreeement with Schering-Plough Corp. to further expand its massive cardiovascular offering. Roche Pharmaceuticals has acquired Genentech Inc. for $46.8...

  • Drug companies' landscape changing. Yeats, Jodi // New Zealand Doctor;9/23/2009, p33 

    The article reports on the merger and acquisition activity in the New Zealand drug industry as of September 23, 2009. Regulatory approval is being sought by Merck & Co. and Schering-Plough in countries they operate in to push the merger. Both companies have not discussed changes in operations...

  • MERCK & CO., INC.  // Contract Pharma;Jul/Aug2012, Vol. 14 Issue 6, p58 

    The article profiles Merck & Co. Inc. located in New Jersey, the number four company in the list of the top 20 pharma in the July/August 2012 issue of the journal "Contract Pharma." It says that a new wave of layoffs and shutdowns, following the 2009 restructuring that went down after the...

  • Merck Eyes 'Strong Start'.  // Chain Drug Review;11/23/2009, Vol. 31 Issue 20, p43 

    The article reports on the acquisition of Schering-Plough Corp by Merck & Co. Inc. which has became the world's second-largest drug manufacturer following Pfizer Inc. Richard Clark, chief executive officer of Merck, mentions that the acquisition has placed the company to be ready in delivering...

  • Merck & Co. to Acquire Schering-Plough for $41 billion. Ramesh, Deepti // Chemical Week;3/16/2009, Vol. 171 Issue 8, p43 

    The article reports on the decision of Merck & Co. to acquire Schering-Plough. The deal, estimated at $41.1 billion in stock and cash, will create a megapharma company with combined sales of $47 billion. Under the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in...

  • Merck strengthens drug pipeline in rival takeover.  // Nature;3/12/2009, Vol. 458 Issue 7235, p137 

    The article discusses the acquisition by the of U.S. pharmaceutical company Merck of its rival Schering-Plough in a deal which was unanimously approved by the boards of both companies. The decision is viewed as a way to protect Merck's drug-development pipeline. The new company will called by...

  • THE NEW MSD. Col√≥n, Cynthia // Caribbean Business;5/27/2010, Vol. 38 Issue 20, pB4 

    The article profiles the pharmaceutical company Merck & Co. Inc. in iPuerto Rico, known as MSD outside the U.S.. It notes that the company is a worldwide leader in offering distinct products, and innovative services which have bettered the lives of consumers. It mentions that after the merger...

  • Merck and Schering-Plough to merge.  // TCE: The Chemical Engineer;Apr2009, Issue 814, p5 

    The article deals with the decision of Merck & Co. to pay $41 billion to acquire pharmaceutical firm Schering-Plough. The boards of both companies have approved the offer, which is a 34 percent premium on the March 6, 2009 share price of Schering-Plough. An annual cost-savings of $3.5 billion is...

  • TOP 20 PHARMA: #6 MERCK.  // Contract Pharma;2009, Vol. 11 Issue 6, p62 

    The article features New Jersey-based Merck & Co. Inc. which ranked sixth in the top 20 pharmaceutical companies in 2009. According to Merck president Richard T. Clark, they acquired Schering-Plough Corp. worth 41 billion dollars in March 2009 because it will help in the growth and expansion of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics